General Information of Drug (ID: DMQD1GN)

Drug Name
JNJ-32729463
Synonyms
Acorafloxacin HCl; Avarofloxacin hydrochloride; Acorafloxacin hydrochloride; UNII-1NWW5SKQ0N; JNJ-32729463-AAC; 1NWW5SKQ0N; Acorafloxacin hydrochloride [USAN]; 1001162-01-1 (HCl); Acorafloxacin hydrochloride (USAN); Avarofloxacin HCl; 1001162-01-1; (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; JNJ-Q2 hydrochloride; SCHEMBL2190495; CHEMBL2364603; DTXSID70142966; JNJ-32729463AAC; Jnj-32729463; 7-((3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride; D10544; Q27252661
Indication
Disease Entry ICD 11 Status REF
Community-acquired pneumonia CA40.Z Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 455.9
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 5
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 9
Chemical Identifiers
Formula
C21H24ClF2N3O4
IUPAC Name
7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
Canonical SMILES
COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl
InChI
InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24;/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29);1H/b16-11+;
InChIKey
RDXCNSOGHLLWDV-YFMOEUEHSA-N
Cross-matching ID
PubChem CID
67311433
CAS Number
1001162-01-1
TTD ID
D39VXL
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Inhibitor [2]
Bacterial DNA topoisomerase 4A (Bact parC) TTFK8YB PARC_ECOLI Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01198626) Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia. U.S. National Institutes of Health.
2 Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.